Interferons in melanoma

Current Opinion in Oncology

Volumn 8, Issue 2, 1996, Pages 167-174

  Agarwala, Sanjiv S ^a   Kirkwood, John M ^a  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; ALPHA2B INTERFERON; BLEOMYCIN; CANCER VACCINE; CARBOPLATIN; CARMUSTINE; CISPLATIN; DACARBAZINE; GAMMA INTERFERON; INTERFERON; INTERLEUKIN 2; LOMUSTINE; MELPHALAN; RETINOIC ACID; TAMOXIFEN; TUMOR NECROSIS FACTOR ALPHA; VINBLASTINE; VINCRISTINE;

CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CLINICAL TRIAL; HUMAN; MAJOR CLINICAL STUDY; MELANOMA; METASTASIS; MULTICENTER STUDY; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; REVIEW; SKIN CANCER; SUBCUTANEOUS DRUG ADMINISTRATION; VACCINATION;

EID: 0029951060     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-199603000-00015     Document Type: Review

References (57)

1. Issacs A, Lindenman J: Virus interference: the interferon. Proc Royal Soc (London) 1957, 147:258-267.
2. Kirkwood JM: Melanoma. In Biologic Therapy of Cancer, edn 2. Edited by DeVita VT Jr, Hellman S, Rosenberg SA. Philadelphia: JB Lippincott; 1995:388-411.
3. Kirkwood JM, Agarwala S: Systemic cytotoxic and biologic therapy melanoma. PPO Updates 1993, 7:1-16.
4. Creagan ET, Ahmann DL, Frytak S, Long HJ, Chang MN, Itri LM: Phase II trials of recombinant leukocyte A interferon in disseminated malignant melanoma: results in 96 patients. Cancer Treat Rep 1986, 70(suppl 5):619-624.
5. McLeod GRC, Thomson DB, Hersey P: Recombinant interferon alfa-2a in advanced malignant melanoma: a phase I-II study in combination with DTIC. Int J Cancer 1987, (suppl 1):31-35.
6. Kirkwood JM, Ernstoff MS, Guiliano AE: Interferon α-2a and dacarbazine in melanoma. J Natl Cancer Inst 1990, 82:1062-1063.
7. Grundersen S, Flokkmann A: Interferon plus dacarbazine in advanced malignant melanoma: a phase I-II study. Eur J Cancer 1991, 27(suppl 2):220-221.
8. Mulder NH, de Vries EGE, Sleijfer DT, Schraffordt Koops H, Willemse PHB: Dacarbazine (DTIC), human recombinant interferon α 2a (Roferon) and 5-fluorouracil for disseminated malignant melanoma. Br J Cancer 1992, 65:303-304.
9. Buter J, Sleijfer DT, Willemse PH, van der Graaf WT, de Vries EG, Schraffordt Koops H, Mulder NH: Dose escalation of dacarbazine combined with interferon α-2a, G-CSF and ondansetron in patients with metastatic melanoma. Anticancer Res 1994, 14:1325-1328.
10. Thompson JA, Shulman KL, Benyunes MC, Lindgren CG, Collins G, Lange PH, Bush WH Jr, Benz LA, Fefer A: Prolonged continuous intravenous infusion interleukin-2 and lymphokine-activated killer-cell therapy for metastatic renal cell carcinoma. J Clin Oncol 1992, 10(suppl 6):960-968.
11. Bajetta E, DiLeo A, Zampino MG, Sertoli MR, Cornella G, Barduagni M, Giannotti B, Queirolo P, Tribbia G, Bernengo MG: Multicenter randomized trial of dacarbazine alone or in combination with two different doses and schedules of interferon alfa-2a in the treatment of advanced melanoma. J Clin Oncol 1994, 12:806-811.
12. Falkson CI, Falkson G, Falkson HC: Improved results with the addition of interferon alfa-2b to dacarbazine in the treatment of patients with metastatic malignant melanoma. J Clin Oncol 1991, 9(suppl 8):1403-1408.
13. Atzpodien J, Lopez Hanninen E, Kirchner H, Franzke A, Korfer A, Volkenandt M, Duensing S, Schomburg A, Chaitchik S, Poliwoda H: Chemoimmunotherapy of advanced malignant melanoma: sequential administration of subcutaneous interleukin-2 and interferon-α after intravenous dacarbazine and carboplatin or intravenous dacarbazine, cisplatin, carmustine and tamoxifen. Eur J Cancer 1995, 31A:876-881.
14. Vorobiof DA, Bezwoda WR: A randomized trial of vindesine plus interferon-α 2b compared with interferon-α 2b or vindesine alone in the treatment of advanced malignant melanoma. Eur J Cancer 1994, 30A:797-800.
15. Del Prete SA, Maurer LH, O'Donnell J, Forcier RJ, LeMarbre P: Combination chemotherapy with cisplatin, carmustine, dacarbazine and tamoxifen in malignant melanoma. Cancer Treat Rep 1984, 68(suppl 11):1403-1405.
16. Richards JM, Mehta N, Ramming K, Skosey P, et al.: Sequential chemoimmunotherapy in the treatment of metastatic melanoma. J Clin Oncol 1992, 8:1338-1343.
17. Hahka-Kemppinen M, Muhonen T, Virolainen M, Jekunen A, Asko-Selgavaara S, Pyrhönen S: Response of subcutaneous and cutaneous metastases of malignant melanoma to combined cytostatic plus interferon therapy [abstract]. Br J Dermatol 1995, 132:973-977.
18. Buzaid AC, Legha SS: Combination of chemotherapy with interleukin-2 and interferon-alfa for the treatment of advanced melanoma. Semin Oncol 1994, 21:23-28.
19. Rosenberg SA, Lotze MT, Yang JC, Linehan WM, Seipp C, Calabro S, Karp SE, Sherry RM, Steinberg S, White DE: Combination therapy with interleukin-2 and α-interferon for the treatment of patients with advanced cancer. J Clin Oncol 1989, 7(suppl 12):1863-1874.
20. Lee KH, Talpaz M, Rothberg JM, Murray JL, Papadopoulos N, Plager C, Benjamin R, Levitt D, Gutterman J: Concomitant administration of recombinant human interleukin-2 and recombinant interferon-α 2a in cancer patients: a phase I study. J Clin Oncol 1989, 7:1726-1732.
21. Bukowski RM, Murthy S, Sergi J: Phase I trial of continuous infusion recombinant interleukin-2 and intermittent recombinant interferon-α: clinical effects. J Biol Response Mod 1990, 9:538-545.
22. Marincola FM, White DE, Wise AP, Rosenberg SA: Combination therapy with interferon alfa-2a and interleukin-2 for the treatment of metastatic cancer. J Clin Oncol 1995, 13(suppl 5):1110-1122.
23. Keilholz U, Scheibenbogen C, Tilgen W, Bergmann L, Weidmann E, Seither E, Richter M, Brado B, Mitrou PS, Hunstein W: Interferon-α and interleukin-2 in the treatment of metastatic melanoma: comparison of two phase II trials. Cancer 1993, 72(suppl 2):607-614.
24. Khayat D, Borel C, Tourani JM, Benhammouda A, Antoine E, Rixe O, Vuillemin E, Bazex PA, Thill L, Franks R, Auclerc G, Soubrane C, Banzet P, Weil M: Sequential chemoimmunotherapy with cisplatin, interleukin-2, and interferon alfa-2a for metastatic melanoma. J Clin Oncol 1993, 11(suppl 11):2173-2180.
25. Dorval T, Paris S, Chevreau C, Baume D, Cupissol D, Oskam R, de Peuter MA, Herrera A, Escudier B: Results of French multicentric randomized trial of chemoimmunotherapy (cisplatin [P], IL-2 [Proleukin]), with or without IFN (Roferon) in metastatic malignant melanoma [abstract]. Proc Am Soc Clin Oncol 1994, 13:395.
26. Levy DE: Cytoplasmic Events in Signal Transduction Leading to IFN α-induced Gene Expression. In Interferon: Principles and Medical Applications, edn 1. Edited by Baron S, Coppenhaver DH, Dianzani F, Fleischmann WR Jr, Hughes TK Jr, Kumpel GR, Niesel DW, Stanton GJ, Tyring SK. Galveston: The University of Texas Medical Branch; 1992:161-173.
27. Fu X-Y, Kessler DS, Veals SA, Levy DE, Darnell JE Jr: ISGF3, the transcriptional activator induced by interferon α, consists of multiple interacting polypeptide chains. Proc Natl Acad Sci U S A 1990, 87:8555-8559.
28. Levy D, Darnell JE Jr: Interferon-dependent transcriptional activation: signal transduction without second messenger involvement? New Biol 1990, 2(suppl 10):923-928.
29. Creagan ET, Loprinzi CL, Ahmann DL, Schaid DJ: A phase I-II trial of the combination of recombinant leukocyte A interferon and recombinant human interferon-gamma in patients with metastatic malignant melanoma. Cancer 1988, 62:2472-2474.
30. Osanto S, Janse R, Naipal AMIH, Gratama J-W, van Leeuwen A, Cleton FJ: In vivo effects of combination treatment with recombinant interferon-gamma and -α in metastatic melanoma. Int J Cancer 1989, 43:1001-1006.
31. Dhingra K, Papadopoulos N, Lippman S, Lotan R, Legha SS: Phase II study of α-interferon and 13-cis-retinoic acid in metastatic melanoma. Invest New Drugs 1993, 11:39-43.
32. Fierlbeck G, Schreiner T, Rassner G: Combination of highly purified human leukocyte interferon α and 13-cis-retinoic acid for the treatment of metastatic melanoma. Cancer Immunol Immunother 1995, 40:157-164.
33. Creagan ET, Ahmann DL, Green SJ, Long HJ, Frytak S, Itri LM: Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 1985, 3(7):977-981.
34. Creagan ET, Long HJ, Ahmann DL, Schaid DJ: Phase II assessment of recombinant leukocyte A interferon with difluoromethylorinithine in disseminated malignant melanoma. Am J Clin Oncol 1990, 13:218-220.
35. Miller RL, Steis RG, Clark JW, Smith JW II, Crum E, McKnight JE, Hawkins MJ, Jones MJ, Longo DL, Urba WJ: Randomized trial of recombinant α2b-interferon with or without indomethacin in patients with metastatic malignant melanoma. Cancer Res 1989, 49(suppl 7):1871-1876
36. Harris J, Bines S, Das Gupta T: Therapy of disseminated malignant melanoma with recombinant alfa-2b interferon and piroxicam: clinical results with a report of an unusual response-associated feature (vitiligo) and unusual toxicity (diffuse pulmonary interstitial fibrosis). Med Ped Oncol 1994, 22:103-106.
37. Ernstoff MS, Trautman T, Davis CA, Reich SD, Witman P, Balser J, Rudnick S, Kirkwood JM: A randomized phase I/II study of continuous versus intermittent intravenous interferon gamma in patients with metastatic melanoma. J Clin Oncol 1987, 5(suppl 11):1804-1810.
38. Thompson JA, Cox WW, Lindgren CG, Collins C, Neraas KA, Bonnem EM, Fefer A. Subcutaneous recombinant gamma interferon in cancer patients: toxicity, pharmacokinetics, and immunomodulatory effects. Cancer Immunol Immunother 1987, 25:47-53.
39. Lienard D, Ewalenko P, Delmotte JJ, et al.: High dose recombinant tumor necrosis factor α in combination with interferon gamma and melphalan in isolation perfusion of the limbs for melanoma and sarcoma. J Clin Oncol 1992, 10:52-60.
40. Lienard D, Lejeune FJ, Ewalenko P: In transit metastases of malignant melanoma treated by high dose rTNFα in combination with inteferon-gamma and melphalan in isolation perfusion. World J Surg 1989, 13:598-602.
41. Fraker DL, Alexander HR: The use of tumor necrosis factor in isolated limb perfusions for melanoma and sarcoma. PPO Updates 1993, 7:1-10.
42. Lienard D, Eggermont AM, Schraffordt Koops H, Lejeune FJ: High doses of rTNF-alpha, rINF-gamma and melphalan in isolation perfusion produce 90% CR in melanomas in-transit metastasis [abstract]. Ann Oncol 1992, 3(suppl 5):160.
43. Thom AK, Alexander HR, Andrich MP, Barker WC, Rosenberg SA, Fraker DL: Cytokine levels and systemic toxicity in patients undergoing isolated limb perfusion with high-dose tumor necrosis factor, interferon gamma, and melphalan. J Clin Oncol 1995, 13:264-273.
44. Cumberlin R, DeMoss E, Lassus M. Isolation perfusion for malignant melanoma of the extremity. J Clin Oncol 1985, 3:1022.
45. Creagan ET, Dalton RJ, Ahmann DL, Jung S, Morton RF, Langdon RM Jr, Kugler J, Rodrigue U: Randomized, surgical adjuvant clinical trial of recombinant interferon alfa-2a in selected patients with malignant melanoma. J Clin Oncol 1995, 13:2776-2783.
46. Cascinelli N: Evaluation of efficacy of adjuvant rIFNα 2A in melanoma patients with regional node metastases [abstract]. Proc Am Soc Clin Oncol 1995, 14:410.
47. Meyskens FL Jr, Kopecky K, Samson M, Hersh E, MacDonald J, Jaffe H, Crowley J, Coltman C: Recombinant human interferon gamma: adverse effects in high-risk stage I and II cutaneous malignant melanoma. J Natl Cancer Inst 1990, 82(suppl 12):1071.
48. Meyskens FL Jr, Kopecky KJ, Taylor CW, Noyes RD, Tuthill RJ, Hersh EM, Feun LG, Doroshow JH, Flaherty LE, Sondak VK: Randomized trial of adjuvant human interferon gamma versus observation in high-risk cutaneous melanoma: a Southwest Oncology Group study. J Natl Cancer Inst 1995, 87:1710-1713.
49. Livingston PO, Wong GYC, Adluri S: A randomized trial of adjuvant vaccination with BCG versus BCG plus the melanoma ganglioside GM2 in patients with AJCC stage III melanoma. J Clin Oncol 1994, 12:1036-1044.
50. Wallack MK, Sivanandham M: Clinical trials with VMO for melanoma. Ann NY Acad Sci 1993, 690:178-189.
51. Mitchell MS, Jakowatz J, Harel W, Dean G, Stevenson L, Boswell WD, Groshen S: Increased effectiveness of interferon α-2B following active specific immunotherapy for melanoma. J Clin Oncol 1994, 12:402-411.
52. Hamblin TJ, Davies B, Sadullah S, Oskam R, Palmer P, Franks CR: A phase II study of the treatment of metastatic malignant melanoma with a combination of dacarbazine, cisplatin, interleukin-2 (IL-2) and alfa-interferon (IFN) [abstract]. Proc Am Soc Clin Oncol 1991, 10:294.
53. Pyrhönen S, Hahka-Kemppinen M, Muhonen T: A promising interferon plus four-drug chemotherapy regimen for metastatic melanoma. J Clin Oncol 1992, 10:1919-1926.
54. Legha SS, Buzaid AC, Bedikian A, Eton O, Plager C, Benjamin R: Efficacy of concurrent biochemotherapy using interleukin-2 (IL-2) + interferon alfa-2a (IFN) and chemotherapy with cisplatin (C), vinblastine (V) and DTIC (D) in metastatic melanoma [abstract]. Proc Annu Meet Am Assoc Cancer Res 1994:35.
55. Wiernik PH, Einzig AI: Taxol in malignant melanoma. Monographs of the NCI 1993, 15:185-187.
56. Vuoristo MS, Grohn P, Kellokumpu-Lehtinen P, Kumpulainen E, Turunen M, Korpela M, Joensuu H, Tiusanen K, Nevantaus A: Intermittent interferon and polychemotherapy in metastatic melanoma. J Cancer Res Clin Oncol 1995, 121:175-180.
57. Keilholz U, Scheibenbogen C, Stoelben E, Saeger HD, Hunstein W: Immunotherapy of metastatic melanoma with interferon-α and interleukin-2: pattern of progression in responders and patients with stable disease with or without resection of residual lesions. Eur J Cancer 1994, 30A:955-958.